Browse > Article

Effects of 0.1% Tacrolimus on Canine Skin Mast Cells and Eosinophils  

Jeong, A Young (Laboratory of Veterinary Internal Medicine, Kyungpook National University)
Bae, Seulgi (Laboratory of Veterinary Internal Medicine, Kyungpook National University)
Oh, Taeho (Laboratory of Veterinary Internal Medicine, Kyungpook National University)
Publication Information
Journal of Veterinary Clinics / v.31, no.2, 2014 , pp. 95-101 More about this Journal
Abstract
Five dogs were used to determine whether 0.1% tacrolimus ointment application for one day would inhibit IgE-mediated late-phase reactions (LPRs). It was consisted of three periods: one period without therapeutic administration (control) and two periods of treatment with either the tacrolimus ointment or vehicle. Induction of IgE-mediated LPRs was induced by intradermal injections of 0.05 ml (0.14 mg/ml) of solution of goat anti-canine IgE polyclonal antibodies. Each section for mast cells (MCs) and eosinophils (EPs) was stained with acidified toluidine blue, and Luna's stain, respectively. Assessment of anti-inflammatory effect of tacrolimus ointment composed of cell counts of MC and EP from lesions of induced LPR. In normal canine biopsies, the number of dermal MCs and EPs were $12.3{\pm}1.4cells/mm^2$ and $3.1{\pm}1.3cells/mm^2$, respectively. MC counts dramatically decreased at time dependent manner after anti-IgE administration. However, the number of MCs on 6 hours after challenge was significantly less decreased in the groups treated with the tacrolimus, as compared with control and vehicle group. The number of EPs on 24 hours after challenge was significantly lower in the group treated with the tacrolimus than in the control and vehicle groups. In conclusion, this study revealed that 0.1% tacrolimus ointment in dogs may exert a potent anti-inflammatory effect on inhibition of MC degranulation and also secondary prevention of EP infiltration during LPR.
Keywords
tacrolimus; mast cell; eosinophil; late-phase reaction; atopic dermatitis; dog; FK-506;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Yong LC, Watkins S, Wilhelm DL. The mast cell: distribution and maturation in the peritoneal cavity of the adult rat. Pathology. 1975; 7: 307-318.   DOI
2 Scott D.W, Miller W.H., Griffin C.E. Small Animal Dermatology 6th ed. Philadelphia: WB Saunders, 2001: 232-233.
3 Soter NA, Fleischer AB Jr, Webster GF, Monroe E, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, Safety. J Am Acad Dermatol 2001; 44: S39-S46.   DOI   ScienceOn
4 Vogelnest LJ, Mueller RS, Dart CM. The suitability of medetomidine sedation for intradermal skin testing in dogs. Vet Dermatol 2000; 11: 285-290.   DOI   ScienceOn
5 Zweiman B. The late-phase reaction: role of IgE, its receptor and cytokines. Curr Opin Immunol 1993; 5: 950-955.   DOI   ScienceOn
6 Rivierre C, Dunston SM, Olivry T. Effects of a 1 per cent hydrocortisone conditioner on the prevention of immediate and late-phase reactions in canine skin. Vet Rec 2000; 147; 739-742.
7 Olivry T, Sousa CA. The ACVD task force on canine atopic dermatitis(XIX): general principles of therapy. Vet Immunol Immunopathol 2001; 81: 311-316.   DOI   ScienceOn
8 Oranje AP, de Waard-van der Spek FB. Atopic dermatitis: review 2000 to January 2001. Curr Opin Pediatr 2002; 14: 410-413.   DOI   ScienceOn
9 Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44: S47-57.   DOI   ScienceOn
10 Rubins A, Gutmane R, Valdmane N, Stevenson P, Foster C, Undre N. Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. J Invest Dermatol 2005; 125: 68-71.   DOI   ScienceOn
11 Sakuma S, Higashi Y, Sato N, Sasakawa T, Sengoku T, Ohkubo Y, Amaya T, Goto T. Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. Int Immunopharmacol 2001: 1: 1219-1226.   DOI   ScienceOn
12 Satoh T, Tahara E, Yamada T, Watanabe C, Itoh T, Terasawa K, Nagai H, Saiki I. Differential effect of antiallergic drugs on IgE-mediated cutaneous reaction in passively sensitized mice. Pharmacology 2000; 60: 97-104.   DOI   ScienceOn
13 Sawada S, Suzuki G, Kawase Y, Takaku F. Novel immunosuppressive agent, FK506 in vitro effects on the cloned T cell activation. J Immunol 1987; 139: 1797-1803.
14 Sayama K, Diehn M, Matsuda K, Lunderius C, Tsai M, Tam SY, Botstein D, Brown PO, Galli SJ. Transcriptional response of human mast cells stimulated via the Fc(epsilon)RI and identification of mast cells as a source of IL-1. BMC Immunol 2002; 3: 5.   DOI
15 Scott DW, Miller WH, Griffin CE. Small Animal Dermatology 6th ed. Philadelphia: WB Saunders, 2001: 574-601.
16 Marsella R, Nicklin CF, Saglio S, Lopez J. Investigation on the effects of topical therapy with 0.1% tacrolimus ointment (Protopic) on intradermal skin test reactivity in atopic dogs. Vet Dermatol 2004; 15: 218-224.   DOI   ScienceOn
17 Lauerma AI, Surber C, Maibach HI. Absorption of topical tacrolimus (FK506) in vitro through human skin: Comparison with cyclosporin A. Skin Pharmacol 1997; 10: 230-234.   DOI
18 Lauerma AI, Granlund H, Reitamo S. Use of the newer immunosuppressive agents in dermatology. BioDrugs 1997; 8: 96-106.   DOI
19 Leiferman KM, Fujisawa T, Gray BH, Gleich GJ. Extracellular deposition of eosinophil and neutrophil granule proteins in the IgE-mediated cutaneous late phase reaction. Lab Invest 1990; 62: 579-589.
20 Marsella R, Nicklin CF, Saglio S, Lopez J. Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, doubleblinded, placebo-controlled, cross-over study. Vet Dermatol 2004; 15: 294-303.   DOI   ScienceOn
21 Marsella R, Nicklin CF. Investigation on the use of 0.3% tacorlimius lotion for canine atopic dermatitis: a pilot study. Vet Dermatol 2002; 13: 203-210.   DOI   ScienceOn
22 Meingassner JG, Stütz A. Immunosuppressive macrolides of the type FK 506: A novel class of topical agents for treatment of skin disease? J Invest Dermatol 1992; 98: 851-855.   DOI   ScienceOn
23 Moqbel R, Levi-Schaffer F, Kay AB. Cytokine generation by eosinophils. J Allergy Clin Immunol. 1994; 94: 1183-1188.   DOI   ScienceOn
24 Olivry T, Naydan DK, Moore PF. Characterization of the cutaneous inflammatory infiltration in canine atopic dermatitis. Am J Dermatopathol 1997; 19: 477-486.   DOI   ScienceOn
25 Olivry T, Dunston SM, Murphy KM, Moore PF. Characterization of the inflammatory infiltrate during IgE-mediated late phase reactions in the skin of normal and atopic dogs. Vet Dermatol 2001; 12; 49-58.   DOI   ScienceOn
26 Hill PB, Hillier A, Olivry T. The ACVD task force on canine atopic dermatitis (VI): IgE-induced immediate and late-phase reactions, two inflammatory sequences at sites of intradermal allergen injections. Vet Immunol Immunopathol 2001; 81: 199-204.   DOI   ScienceOn
27 Griffin CE, Hillier A. The ACVD task force on canine atopic dermatitis (XXIV): allergen-specific immunotherapy. Vet Immunol Immunopathol 2001; 81: 363-383.   DOI   ScienceOn
28 Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994; 94: 870-876.   DOI   ScienceOn
29 Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, effeicacy. J Am Acad Dermatol 2001; 44: S28-S38.   DOI   ScienceOn
30 Hillier A, DeBoer DJ. The ACVD task force on canine atopic dermatitis (XVII): Intradermal testing. Vet Immunol Immunopathol 2001; 81: 289-304.   DOI   ScienceOn
31 Kapp A. The role of eosinophils in the pathogenesis of atopic dermatitis--eosinophil granule proteins as markers of disease activity. Allergy 1993; 48: 1-5.
32 Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka H. FK-506, a novel immunosuppressant isolated from a Streptomyces I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiotics 1987; 40: 1249-1255.   DOI
33 Kohyama T, Takizawa H, Kawasaki S, Akiyama N, Sato M, Ito K, Yamamoto K. A potent immunosuppressant FK506 inhibits IL-8 expression in human eosinophils. Mol Cell Biol Res Commun 1999; 1: 72-77.   DOI   ScienceOn
34 Kube P, Audigé L, Küther K, Welle M. Distribution, density and heterogeneity of canine mast cells and influence of fixation techniques. Histochem Cell Biol. 1998; 110: 129-135.   DOI   ScienceOn
35 Auxilia ST, Hill PB. Mast cell distribution, epidermal thickness and hair follicle density in normal canine skin: possible explanations for the predilection sites of atopic dermatitis? Vet Dermatol 2000; 11: 247-254.   DOI   ScienceOn
36 Bensignor E, Olivry T. Treatment of localized lesions of canine atopic dermatitis with tacrolimus ointment: a blinded randomized controlled trial. Vet Dermatol 2005; 16: 52-60.   DOI   ScienceOn
37 Bieber T. Atopic dermatitis. Ann Dermatol 2010; 22: 125-137.   DOI   ScienceOn
38 Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998; 102: 637-644.   DOI   ScienceOn
39 Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41: 813-851.   DOI   ScienceOn
40 Fleischer AB Jr, Ling M, Eichenfield L, Satoi Y, Jaracz E, Rico MJ, Maher RM. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002;47: 562-570   DOI   ScienceOn
41 Frew AJ, Kay AB. The relationship between CD4+ lymphocytes, activated eosinophils and the magnitude of the allergen-induced late phase skin reaction in man. J Immunol 1988; 141: 4158-4164.